M

MESA LABORATORIES INC /CO/

MLAB Nasdaq Technology · Industrial Instruments for Measurement, Display, and Control Lakewood, CO www.mesalabs.com
$126.79
Mkt Cap 700.5M
In this annual report, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as we, us, our, the Company, or Mesa. Mesa was organized in 1982 as a…

In this annual report, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as we, us, our, the Company, or Mesa. Mesa was organized in 1982 as a Colorado corporation. General We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and the Asia Pacific region ("APAC"), and by independent distributors throughout the world. We are headquartered in Lakewood, Colorado and our common stock is listed for trading on the Nasdaq Global Market ( Nasdaq ) under the symbol MLAB. Our fiscal year ends on March 31. References in this annual report to a particular fiscal year, year or year-end refer to our fiscal year. Strategy We strive to create stakeholder value and further our purpose of Protecting the Vulnerable by growing our business both organically and through acquisitions, by improving our operating efficiency, and by continuing to hire, develop and retain top talent. As a business, we commit to our purpose of Protecting the Vulnerable every day by taking a customer-focused approach to developing, building and delivering our products and services.

/100 Overall
Calculating score…
Running full analysis
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$249.7M
FCF TTM
$52.9M
P/E RATIO
145.9x
P/FCF
13.3x
Running full 6-factor analysis…